Aprea Therapeutics (APRE) Net Cash Flow (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Net Cash Flow of $31.9 million for Q1 2026, up 991.32% year-over-year from $2.9 million in Q1 2025, and up 3520.15% quarter-over-quarter from $880278.0 in Q4 2025.
Aprea Therapeutics (APRE) Net Cash Flow (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Net Cash Flow for 9 consecutive years, with $31.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 991.32% year-over-year to $31.9 million; the TTM figure through Mar 2026 stood at $27.2 million (up 307.68% YoY), while the FY2025 annual figure was -$8.3 million, down 760.5% from the prior year.
- Net Cash Flow advanced to $31.9 million in Q1 2026 per APRE's latest filing, from $880278.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $31.9 million in Q1 2026 and bottomed at -$8.9 million in Q2 2022.
- Historically, Net Cash Flow has averaged -$417321.0 across 5 years, with a median of -$3.2 million in 2023.
- Annual changes were most pronounced in 2025 — Net Cash Flow slumped 133.21% — and 2026, when it jumped 991.32%.
- Aprea Therapeutics' Net Cash Flow stood at -$3.9 million in 2022, then grew by 4.47% to -$3.7 million in 2023, then increased by 9.88% to -$3.4 million in 2024, then surged by 126.07% to $880278.0 in 2025, then soared by 3520.15% to $31.9 million in 2026.
- Business Quant data shows APRE's Net Cash Flow at $31.9 million in Q1 2026, $880278.0 in Q4 2025, and -$2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | -5.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.22 Mn |
| Jun 30, 2026 | -5.22 Mn |
| Mar 31, 2026 | 31.87 Mn |
| Mar 31, 2026 | 31.87 Mn |
| Dec 31, 2025 | 880,278.00 |
| Dec 31, 2025 | 880,278.00 |
| Sep 30, 2025 | -2.81 Mn |
| Sep 30, 2025 | -2.81 Mn |
| Jun 30, 2025 | -2.75 Mn |
| Jun 30, 2025 | -2.75 Mn |
| Mar 31, 2025 | -3.58 Mn |
| Mar 31, 2025 | -3.58 Mn |
| Dec 31, 2024 | -3.38 Mn |
| Dec 31, 2024 | -3.38 Mn |
| Sep 30, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.47 Mn |
| Jun 30, 2024 | -3.67 Mn |
| Jun 30, 2024 | -3.67 Mn |
| Mar 31, 2024 | 10.77 Mn |
| Mar 31, 2024 | 10.77 Mn |